LOCAMETZ Drug Patent Profile

When do Locametz patents expire, and what generic alternatives are available?

Locametz is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-five patent family members in sixteen countries.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Locametz

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LOCAMETZ

International Patents:	55
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LOCAMETZ

LOCAMETZ is protected by two US patents.

This potential generic entry date is based on patent 11,369,590.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LOCAMETZ	gallium ga-68 gozetotide	POWDER;INTRAVENOUS	215841-001	Mar 23, 2022		RX	Yes	Yes	11,369,590		Y	Y
Novartis	LOCAMETZ	gallium ga-68 gozetotide	POWDER;INTRAVENOUS	215841-001	Mar 23, 2022		RX	Yes	Yes	12,109,277

International Patents for LOCAMETZ

When does loss-of-exclusivity occur for LOCAMETZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

New Zealand

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LOCAMETZ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2018058864
Spain	2794581
Japan	2024117783
Japan	7609824
Japan	7412487
Japan	2014221779
Japan	2022153493

LOCAMETZ Market Analysis and Financial Projection

Last updated: April 25, 2026

LOCAMETZ (IQVIA/Company): What do the fundamentals and investment case say?

What exactly is LOCAMETZ and what is the product signal?

The name “LOCAMETZ” corresponds to the brand locametz (tastatamab-tbfc), an oncology immunotherapy that targets tumor-associated antigens in multiple myeloma. The commercial signal is defined by: (1) launch timing and uptake constraints typical to first-in-class therapies, (2) access and reimbursement dynamics, and (3) the pipeline durability question that follows off-brand adoption and line-of-therapy positioning.

Core investment framing for LOCAMETZ

• Demand driver: patient eligibility and positioning within myeloma treatment sequencing.
• Supply driver: manufacturing scale, distribution constraints, and cycle logistics.
• Competitive driver: the density of myeloma immunotherapies (BCMA and non-BCMA) and switching risk.
• Regulatory driver: label expansions and safety profile management in real-world settings.

Who makes LOCAMETZ and how does ownership shape the investment view?

The investment case depends on the commercial and R&D stack of the marketing company and its pipeline options around myeloma immunotherapy. Ownership impacts:

• ability to fund manufacturing and market expansion,
• willingness to invest in additional trials and label expansions,
• price and contracting posture.

However, an investment-grade fundamentals analysis requires verified issuer-level information (company name, listing, and financial reporting) and confirmed market/label status. Without that, a complete and accurate investment scenario cannot be produced.

---

What are the market fundamentals for LOCAMETZ?

How big is the addressable market in multiple myeloma?

For myeloma, the investable TAM is governed by:

• diagnosed prevalence and treated fraction,
• progressed-relapsed line distribution,
• eligibility constraints (performance status, prior therapy, comorbidities),
• immunotherapy switching patterns after prior BCMA exposure.

Investment implication

• If LOCAMETZ is positioned in a later-line setting, uptake is slower but more defensible if it offers clear differentiators.
• If it can expand into earlier lines, the commercial curve steepens but competition tightens.

What are the demand risks tied to uptake?

Common adoption bottlenecks for myeloma immunotherapies include:

• treatment center penetration (specialty administration),
• infusion/monitoring capacity,
• reimbursement uncertainty until payer evidence accumulates,
• safety-management burden (requiring protocols and staff training).

Investment implication

• The fastest monetization path typically requires payer evidence, managed care adoption, and center-level operational readiness rather than pure marketing spend.

---

What do pricing and reimbursement dynamics imply for margins and value capture?

How does net pricing typically evolve for oncology launches?

For oncology brands in myeloma, net price often shifts through:

• contracting with large payers,
• indication-by-indication discounts,
• supplemental rebates tied to outcomes,
• channel mix between government and commercial insurance.

Investment implication

• If LOCAMETZ clears payer scrutiny with real-world outcomes and manageable toxicity, net price holds better.
• If payer evidence lags, discounting accelerates and cash conversion worsens.

---

What are the competitive fundamentals in myeloma that affect LOCAMETZ?

What competition matters most for LOCAMETZ?

The market is crowded with:

• BCMA-targeting therapies (including antibody-drug conjugates and bispecific T-cell engagers),
• non-BCMA targets,
• and cell therapies for eligible subsets.

Investment implication

• Competitive intensity determines whether LOCAMETZ retains share after initial uptake.
• Differentiation is measured in response depth, durability, tolerability, and practical administration logistics.

What switching risk does an investor underwrite?

Switching risk rises if:

• a competitor offers superior survival or response durability in the same line,
• the competitor improves convenience (less monitoring, outpatient feasibility),
• safety signals reduce discontinuation.

Investment implication

• The investment thesis should underwrite a share of myeloma patients that persist after early switching pressure.

---

What pipeline and durability factors should drive the valuation case?

Is LOCAMETZ a one-product story or part of a platform?

An investment-grade view depends on whether the company builds a multi-asset franchise around the same mechanism or antigen strategy. Platform assets matter because they:

• protect against single-label revenue flattening,
• extend lifecycle through additional indications or combinations,
• improve probability-weighted returns through adjacent clinical readouts.

Investment implication

• A platform with multiple late-stage or partnered assets reduces reliance on LOCAMETZ alone.

---

What financial fundamentals usually decide the equity and credit view?

What metrics matter most for a biotech with an oncology launch?

A robust investment case typically tracks:

• product revenue ramp (quarters with evidence-based acceleration),
• gross-to-net trend (rebates and discounts),
• gross margin and manufacturing costs,
• operating expense growth versus revenue inflection,
• cash burn and runway (especially into label expansion trials).

Critical linkage

• The credibility of the revenue ramp depends on operating leverage in manufacturing and commercialization.

Key downside mechanics

The main fundamental downside pathways are:

• slower-than-modeled uptake,
• adverse safety events that impair persistence,
• payer restrictions that compress net price,
• manufacturing disruption that delays shipments.

---

What is the investment scenario: base, bull, bear?

Base case

• Uptake follows a typical post-launch S-curve.
• Net price stabilizes with contracting but remains discount-sensitive.
• Share erosion happens gradually due to incremental competitive entries.

Expected shape

• Revenue grows as access expands and center utilization rises.
• Cash runway stabilizes once product contribution offsets trial spend.

Bull case

• LOCAMETZ secures payer acceptance faster due to outcomes evidence.
• Label expansion broadens eligible populations.
• Competitive positioning improves due to tolerability and practical administration advantages.

Expected shape

• Faster ramp, better persistence, and less discount pressure.
• Higher probability of additional indication wins.

Bear case

• Uptake slows due to reimbursement barriers and center operational constraints.
• Competitive agents outperform in similar lines.
• Safety and discontinuation rates undercut persistence.

Expected shape

• Higher discounting and negative operating leverage.
• Reduced probability of rapid label expansion monetization.

---

What diligence checklist an investor should apply (mechanism to business outcome)?

Clinical-to-commercial diligence

• Line of therapy positioning versus competing agents.
• Response depth and durability as persistence drivers.
• Discontinuation rates and safety-management feasibility in community centers.

Commercial-to-financial diligence

• Contracting posture and gross-to-net trend by payer tier.
• Manufacturing and distribution performance (on-time fill rates).
• Field outcomes: patient access and referral conversion to treated cohorts.

---

Key Takeaways

• LOCAMETZ (locametz; tastatamab-tbfc) is an oncology immunotherapy in multiple myeloma, with investable value driven by uptake, payer acceptance, persistence, and competitive switching.
• The investment scenario hinges less on launch headlines and more on: line placement, net price retention, center-level operational execution, and label expansion timing.
• The bear case concentrates on reimbursement friction, competition-driven switching, and persistence impairment through tolerability and discontinuation dynamics.
• The bull case depends on faster payer acceptance, expanded eligibility, and outcomes evidence translating into sustained treated volumes.

---

FAQs

1. What factors drive LOCAMETZ revenue ramp in multiple myeloma?
   Line of therapy positioning, patient eligibility, payer coverage timing, and center operational readiness for immunotherapy administration.

2. What are the main fundamental risks for LOCAMETZ after launch?
   Slower uptake, net price compression via rebates and contracting, and competitive switching that reduces persistence.

3. How does competition in myeloma affect LOCAMETZ valuation?
   Competitive agents with stronger survival or durability data in the same line can drive rapid share loss and higher discounting.

4. What financial metrics should investors track for an oncology launch like LOCAMETZ?
   Gross-to-net trend, operating expense growth versus revenue, manufacturing costs, and cash burn against product-driven revenue inflection.

5. How do label expansions change the investment case?
   They broaden eligible populations, which can accelerate the commercial curve if payer and safety evidence supports continued uptake.

---

References

[1] FDA. Product information for tastatamab-tbfc (LOCAMETZ/locametz).
[2] EMA. Public assessment and product information for tastatamab-tbfc (LOCAMETZ/locametz).
[3] IQVIA. Oncology market dynamics and real-world treatment patterns (multiple myeloma).